Inhibikase Therapeutics, Inc. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Inhibikase issued a form of pre-funded warrant to purchase common stock at $0.001 per share exercise price (effectively zero). The warrant shares count and counterparty identity are blank in this template document (to be filled per issuance). The warrant is exercisable anytime after original issue date, with cashless exercise permitted. Key terms: 9.99% beneficial ownership cap (adjustable to 19.99%), standard T+1 settlement, Nasdaq Capital Market as primary trading market, New York law governs.
Why this rating
This is a template form warrant document with blanks unfilled—no specific transaction occurred. Material only when actual terms (share count, counterparty, date) are disclosed in a subsequent 8-K or prospectus supplement.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.